Purpose The objective of this study was to evaluate the potential of PEGylated 64 Cu-liposomes in clinical diagnostic positron emission tomography (PET) imaging and PEGylated 177 Lu-liposomes in internal tumor radiotherapy through in vivo characterization and dosimetric analysis in a human xenograft mouse model. Methods Liposomes with 5 and 10 mol% PEG were characterized with respect to size, charge, and 
Lu radionuclides with PEGylated liposomes, and essentially no leakage of the encapsulated radionuclide was observed upon storage and after serum incubation for 24 h at 37°C. The 10 mol% PEG liposomes showed higher tumor accumulation (6.2 ± 0.2 %ID/g) than the 5 mol% PEG liposomes, as evaluated by PET imaging. The dosimetry analysis of the 64 Cu-liposomes estimated an acceptable total effective dose of 3.3·10 −2 mSv/MBq for diagnostic imaging in patients. A high absorbed tumor dose (114 mGy/ MBq) was estimated for the potential radiotherapeutic 177 Luliposomes. Conclusion The overall preclinical profile of PEGylated 64 Cu-liposomes showed high potential as a new PET theranostic tracer for imaging in humans. Dosimetry results predicted that initial administered activity of 200 MBq of 64 Cu-liposomes should be acceptable in patients. Work is in progress to validate the utility of PEGylated 64 Cu-liposomes in a clinical research programme. The high absorbed tumor dose (114 mGy/MBq) estimated for
Introduction
The most commonly used positron emission tomography (PET) tracer, 2-[
18 F]fluoro-2-deoxy-D-glucose (FDG), has become an important tool for diagnostic and prognostic evaluation of cancer patients as well as for monitoring patient response to therapy [1] [2] [3] [4] [5] . FDG is primarily suitable for diagnosing tumors with high proliferative activity [1, 6] , and has limited diagnostic value for several cancer forms, including highly differentiated neuroendocrine (NE) [7, 8] and prostatic tumors [9, 10] . PET isotopes such as 18 F, 15 O, 13 N and 11 C have relative short half-lives, and thus only early imaging time points are feasible, rendering biological processes several hours or days in duration impossible to explore [11] . Tumor imaging using the longer-lived PET isotope 64 Cu, with favorable decay characteristics (12.7 h), permits study for as long as 48 h after injection [12, 13] . Isotopes emitting beta radiation for short-range local radiation therapy can be used for treatment of tumors if the radioisotopes can be specifically targeted to the diseased tissue. NE tumors are known to express specific tumor markers, and approximately 90 % of NE tumors show overexpression of somatostatin receptors on tumor cell surfaces [14] . Accordingly, these patients are well suited for peptide receptor radionuclide therapy (PRRT), which has been in use approximately 10 years, based on either 90 Y-DOTATOC or 177 Lu-DOTATATE [15] [16] [17] . The doselimiting organs for PRRT are the kidney and bladder, due to renal excretion of the peptide-based tracer, and tracers limiting this absorbed dose to normal organs are needed. Another targeting approach involves the modification of the liposome surface using polymers such as polyethylene glycol (PEG), which results in a sharp reduction of reticuloendothelial system (RES) uptake, thereby prolonging liposome circulation half-life and increasing tumor accumulation through enhanced permeation and retention (EPR) effects [18] .
Several studies investigating PEGylated liposomes have been performed [18] [19] [20] [21] [22] , and the optimum level of PEGylation has been extensively discussed [23] . Moreover, characteristics such as tumor size, cancer type and degree of tumor vascularity have a large impact on the degree of tumor extravasation of PEGylated liposomes. A previous study observed a trend toward higher 111 In-liposome uptake in smaller and more vascular tumors with the use of single-photon emission computed tomography (SPECT) imaging [24] .
Using our recently reported remote loading method to entrap 64 Cu in liposomes [25] , here we report a study to evaluate the diagnostic performance of 64 Cu-loaded PEGylated liposomes in a human xenograft animal model using PET imaging. The study is the first to use PET imaging to investigate the optimal level of PEGylation in liposomes and how this influences the biodistribution and tumor accumulation in tumors of different sizes. The diagnostic potential and safety of 64 Culiposomes as a new PET tracer for clinical use are evaluated through a dosimetry study. In addition, we show new possibilities with the remote loading method by investigating the therapeutic radionuclide, 177 Lu, into PEGylated liposomes. A dosimetric analysis is performed to evaluate the potential and safety of the liposomes as carriers of 177 Lu radionuclides in internal tumor radiotherapy based on the 64 Cu-liposome biodistribution data.
Materials and methods

Preparation of PEGylated liposomes
PEGylated liposomes consisting of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol (CHOL) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000] (DSPE-PEG 2000 ) in a molar ratio of 55:40:5 (5 mol% PEG liposomes) or 50:40:10 (10 mol% PEG liposomes) were prepared as described previously [25] . The size and zeta potential of the liposomes were measured on a ZetaPALS analyser (Brookhaven Instruments, Holtsville, NY, USA). and the lipid concentrations were determined by inductively coupled plasma atomic emission spectroscopy (ICP-OES) (Vista AX; Varian, Inc., Palo Alto, CA, USA). The chelating agent 1,4,7,10-tetraazacyclododecane-1,4,7, 10-tetraacetic acid (DOTA, 10 mM) was trapped within the liposomes during the thin-film hydration process, and DOTA outside the liposomes was removed by size-exclusion chromatography (SEC) (Sephadex G-25) eluted with HEPES buffer (10 mM, pH 7.4, 150 mM NaCl). All lipids were purchased from Avanti Polar Lipids (Alabaster, AL, USA); DOTA was purchased from Macrocyclics (Dallas, TX, USA), and all other chemicals from Sigma-Aldrich (St. Louis, MO, USA).
Cryo-TEM imaging
Electron microscopy studies were performed using a Philips CM120 BioTWIN transmission electron microscope (Philips/ FEI, Hillsboro, OR, USA) with a cryo-holder and a cryotransfer stage. The sample preparation procedure was as described previously [26] . The sample was prepared with a final lipid concentration of 10 mM, and was equilibrated at ambient temperature for 24 h before vitrification. 64 
Cu production
Copper-64 was produced on a PETtrace cyclotron (GE Healthcare, Little Chalfont, UK) equipped with a beamline. Production of 64 Cu was carried out via the 64 Ni(p,n) 64 Cu nuclear reaction described previously [25] . 64 
Cu loading into PEGylated liposomes
The remote loading of 64 Cu into PEGylated liposomes was reported in a recent work [25] . Briefly, 10 μL 2-hydroxyquinoline (2HQ; 0.314 mM) in HEPES buffer (10 mM, pH 7.4, 150 mM NaCl) was added to a dry vial containing radioactive 64 CuCl 2 (~400 MBq). Five hundred microliters of DOTA-containing PEGylated liposomes was added, followed by incubation (60 min). The 64 Cu-liposomes were purified using a Sephadex G-25 column, eluted with HEPES buffer (10 mM, pH 7.4, 150 mM NaCl).
177
Lu loading into PEGylated liposomes 177 Lu-liposomes were prepared and analyzed following the same procedure as for the 64 Cu-liposomes described above. The radioactive 177 LuCl 3 was purchased from PerkinElmer (Waltham, MA, USA).
Liposomal in vitro stability
Purified 64 Cu-liposome or 177 Lu-liposome solutions were tested for radionuclide retention stability by incubation for 24 h at 37°C or 20°C, and the radionuclide retention stability was assayed by measuring the amount of un-encapsulated and encapsulated radionuclides using SEC. Additionally, stability in human serum of the 64 Cu-liposome and 177 Lu-liposome solutions was tested by mixing human serum and liposome solutions (1:1) at 37°C for 24 h, followed by SEC.
Animal models
Human neuroendocrine tumor cells (NCI-H727) (5×10 6 cells) were inoculated in the left and right flanks of female NMRI (Naval Medical Research Institute) nude mice (n=30) in a 1:1 mixture of suspended cells and Matrigel™ (BD Biosciences, San Jose, CA, USA), and were allowed to grow for 3 weeks (small tumors: < 0.5 g; n=26) or 4 weeks (large tumors: > 0.5 g <1.2 g; n=14). All nude mice were purchased from Taconic Biosciences (Borup, Denmark), and all experimental procedures were conducted in adherence to the guidelines set forth by the Danish Ministry of Justice.
Acquisition protocol
Purified PEGylated 64 Cu-liposome suspensions were administered intravenously (i.v.) for biodistribution imaging and quantification. All animals were anesthetized with sevoflurane and catheterized to ensure proper tail vein injection. The average administered lipid dose levels of both liposome formulations (5 mol% PEG and 10 mol% PEG liposomes) were 10 mg/kg (7.8±1.4 MBq/animal) (n=30). After the last PET scan at the 24-h or 48-h time point, the mice were sacrificed, tissues and organs of interest-including the blood, heart, liver, spleen, kidney, lung, small intestine, pancreas, tumors and quadriceps muscle-were harvested, and the level of activity in each tissue was measured using a gamma counter. PET data were acquired on a MicroPET ® Focus 120 (Siemens Medical Solutions, Malvern, PA, USA). The voxel size was 0.866× 0.866×0.796 mm 3 , and the resolution in the centre field of view was 1.4 mm. To ensure proper signal-to-noise ratios, PET scans were acquired over 20 min for the first three scans (1, 8 and 24 h ) and 40 min for the late scan (48 h). Data were reconstructed using the maximum a posteriori (MAP) reconstruction algorithm. For anatomical localization of activity, computed tomography (CT) images were acquired with a MicroCAT ® II system (Siemens Medical Solutions) with Xray tube settings of 62 kVp and 500 μA. CT images were acquired in a 7-min scan with 360 rotation steps, exposure time of 390 ms, and voxel size of 0.095×0.095×0.095 mm 3 .
Data analysis
Following data reconstruction, PET and CT images were fused using Inveon Research Workplace software (Siemens). The emission scans were corrected for random counts and dead time. The PET and CT images were used to identify regions of tracer uptake (source organs) and to generate regions of interest (ROIs). Organs that either were identifiable from the CT image or had tracer uptake significantly above background were used as source organs, and included the spleen, liver, kidney, left ventricle and tumor. In organs where activity could not be accurately measured on PET images, data from the gamma counter were used. Those organs were the lung, intestine and pancreas, due to poor visibility on CT. The blood concentration was measured from the tracer concentration within the left ventricle in the heart [25] . Activity in muscle was quantified by drawing ROIs on the quadriceps muscle, which was well distanced from the tumor in the flank. The percentage of the injected liposomal dose in blood (%ID blood ), the terminal half-life of the liposomal blood clearance (T ½β ) and the mono-exponential function used for description of the injected dose in blood are defined and calculated according to Eqs. 1-3 in Appendix B. The percentage of injected dose per gram (%ID/g) among the different organs and tumors and the standardized uptake value (SUV) are defined and calculated according to Eqs. 4 and 5 in Appendix B. The residence time (T R ) from each source organ is used as input in the OLINDA/EXM software [27] and is calculated according to Eq. 6 in Appendix B. Human absorbed radiation doses were estimated using the standard male phantom, and mean absorbed tumor doses were estimated using the unit density sphere module. The residence time assigned to the remainder-of-body comprises the full-body dose (injected dose) subtracting the source organ doses. This estimate is thus an upper limit since urine excretion was not accounted for.
Statistics
In vivo results are shown as means ± standard error of the mean (SEM). The values were analyzed with a one-tail unpaired t test for significant differences (experiments comparing two groups of animals). P values of less than 0.05 were considered significant.
Results
Characterization of PEGylated liposomes
To evaluate the influence of the degree of PEGylation on tumor accumulation and diagnostic and therapeutic potential, two PEGylated liposome formulations with 5 and 10 mol% DSPE-PEG 2000 were prepared. The mean diameter of liposomes with 5 mol% PEG was 100 nm (PDI=0.025) and of liposomes with 10 mol% PEG was 116 nm (PDI=0.038). The zeta potential was −16.0±0.4 and −17±2 mV, and the phospholipid concentration was 3.4±0.1 and 3.3±0.1 mM for the 5 mol% PEG and 10 mol% PEG liposomes, respectively. Figure  1 shows a cryo-TEM (cryo-transmission electron microscopy) image of PEGylated liposomes containing 10 mol% DSPE-PEG 2000 , where the dominant sample morphology is unilamellar spherical liposomes with sizes in the range 60 −120 nm. 64 
Cu
2+ was remotely loaded into the PEGylated liposomes using 2HQ and DOTA. The 64 Cu loading efficiency of the two liposome formulations was comparable (95± 0.5 % for 5 mol% PEG liposomes and 96±2 % for 10 mol% PEG liposomes; Fig. 2a ) when liposomes were incubated with 64 Cu-2HQ. When the 64 Cu-liposomes were incubated in human serum at 37°C for 24 h, the fraction of radionuclide retained in both PEGylated liposome formulations was greater than 99 % (Fig. 2a inset) .
Loading efficiency and retention stability of PEGylated 177 
Lu-liposomes
The same loading method was used to load 177 Lu 3+ into DOTA-containing liposomes. The Lu PEGylated liposomes were stable with minimal leakage (<1 %) of the encapsulated radionuclide upon storage and after incubation for 24 h at 37°C in serum (Fig. 2b inset) .
Impact of PEGylation on liposomes biodistribution and tumor accumulation
The in vivo performance of PEGylated liposomes was evaluated in the human neuroendocrine carcinoma H727-bearing mouse model by PET imaging analysis. The blood clearance profiles (Fig. 3) were fitted by a mono-exponential curve, and data were treated as described in Appendix B. For 5 mol% PEG liposomes, 40 ± 2 % of the injected dose was cleared from the Culiposomes and free 64 Cu radionuclide using a Sephadex G-25 column. a Preformed liposomes consisting of DSPC/CHOL/DSPE-PEG 2000 (50:40:10) with encapsulated DOTA (10 mM) loaded with 64 Cu using 2HQ showed high loading efficiency (96±2 %, n=10). Inset: A stability test with no leakage of 64 Cu from the 64 Cu-liposomes after incubation in human serum for 24 h at 37°C. b Preformed liposomes consisting of DSPC/CHOL/DSPE-PEG 2000 (50:40:10) with encapsulated DOTA (10 mM) and loaded with 177 Lu using 2HQ with high loading efficiency (96.7±0.3 %, n=4). Inset: A stability test of 177 Lu loaded liposomes with no leakage (<1 %) after incubation in human serum for 24 h at 37°C blood within the first hour, while the remaining circulating dose was cleared with a half-life of T ½β = 10.3± 0.3 h. For 10 mol% PEG liposomes, a significantly lower fraction (30±2 %) of the injected dose was initially cleared from the blood than for the 5 mol% PEG liposomes (P < 0.001). However, the long-circulating portion was cleared at comparable rates for both formulations (10 mol% PEG liposomes, T ½β = 10.7±1.0 h).
The uptake in the spleen after 1 h was relatively high, as expected, and continued to increase throughout the first 24 h, where a peak value for both liposome formulations was reached (Table 1 ). There was no significant difference in the spleen uptake between the two formulations. In contrast, significantly higher uptake of the 10 mol% PEG liposomes compared to the 5 mol% PEG liposomes was observed in the liver after 1 h (P = 0.006) and 8 h (P = 0.004; Table 1 ). However, at 24 and 48 h, the uptake in the liver was comparable between formulations. There was no significant difference in kidney uptake between the two liposome formulations, and the activity localized in the lungs, pancreas and intestine was low for both formulations ( Table 1) . The tumor accumulation of 10 mol% PEG liposomes was significantly higher than that of 5 mol% PEG liposomes at the 24-h (P=0.009) and 48-h (P=0.017) time points (Table 1 ). The T/M ratio of both liposomal formulations was high at all time points, with a peak value (24 h post-injection) of 11.3±1.3 for 5 mol% PEG liposomes and 8.9±0.9 for 10 mol% PEG liposomes, a difference that is borderline significant (P=0.062). Due to higher tumor accumulation of the 10 mol% PEG liposomes, the therapeutic potential of this formulation was further evaluated as a function of tumor size.
Impact of tumor size on tumor accumulation
The tumor accumulation of 10 mol% PEG liposomes was evaluated as a function of tumor size (small tumors [<0.5 g; n=26], large tumors [>0.5<1.2 g; n=14]) and of time (Fig. 4) . A significantly higher liposomal uptake (%ID/g) was observed in small tumors compared to large tumors at the 24-h (P < 0.001) and 48-h (P < 0.001) time points (Fig. 4a) . Additionally, a significant higher T/M ratio was observed within small tumors at 24 h (10.5±0.7; P=0.02) and at 48 h (Fig. 4b) . The tracer accumulation of 10 mol% PEG liposomes in small tumors is depicted in Fig. 5 . Small tumors were visualized with radioactive hot spots distributed throughout the whole tumor area, whereas only the rim of larger tumors had high radioactivity (data not shown), which was similar to findings in a previous study [25] .
Absorbed dose
The distribution data of 5 and 10 mol% PEG liposomes were used for estimating absorbed radiation doses of 64 Cu-liposomes and 177 Lu-liposomes for i.v. injections. For comparison, the liposomal biodistribution data from a clinical study [28] was used to estimate the absorbed radiation doses by including the physical decay of 64 Cu or 177 Lu in determining residence times (Table 2) . For both 5 and 10 mol% PEG 64 Cu-liposomes, the total effective dose was less than 3.3·10 −2 mSv/MBq, and the organs receiving the highest doses were the spleen, liver, stomach wall, lower large intestine wall, red marrow and lungs (Table 3 in Appendix A), with only limited radiation doses absorbed in the kidney and bladder for both formulations. Administration of 200 MBq 64 Cu-liposomes yields a total effective dose of 6.6 and 6.5 mSv for the 10 mol% PEG and 5 mol% PEG 64 Cu-liposomes, respectively. A dose of 9.2 mSv is obtained (200 MBq administration) when calculations are based on liposomal biodistribution data from a clinical study [28] . A total effective dose less than 2.8·10 −1 mSv/ MBq was estimated for both PEGylated 177 Lu formulations (Table 4 in Appendix A), where the organs receiving the highest dose were the spleen, liver, stomach wall, lower large intestine wall, red marrow and lungs for both formulations. The longer-circulating 10 mol% PEG liposomes deposit a higher absorbed dose to the tumor (114 mGy/MBq for a 2-g tumor and 11.5 mGy/MBq for a 20-g tumor) compared to 5 mol% PEG 177 Lu-liposomes (96.9 mGy/MBq for a 2-g tumor and 9.8 mGy/MBq for a 20-g tumor) ( Table 4 in Appendix A).
Discussion
In this study we have evaluated the diagnostic potential of PEGylated 64 Cu-liposomes in a human neuroendocrine carcinoma H727-bearing mouse model using PET imaging, where high T/M ratios for optimal tumor visualization were found for both 5 and 10 mol% PEGylated 64 Cu-liposomes. The loading method used within this study [25] entraps 64 Cu radionuclides in PEGylated liposomes at high concentrations and provides high in vivo stability effective for PET imaging. Imaging agents based on radiolabeled peptides and substrates are of considerable value in nuclear oncology as diagnostic tools, e.g. for NE tumors, but exhibit significantly lower in vivo stability and circulation properties compared to the reported 64 Cu-liposomes. The results obtained within this study look promising when %ID/ g, SUV and T/M ratios are compared with results from radiolabeled peptides [11, 12] . Imaging agents, including radiolabeled peptides and 18 F-FDG, are cleared relatively quickly from the bloodstream through renal clearance, resulting in a high degree of radioactivity in the kidney and bladder. During the imaging period, this high degree of radioactivity in the kidney and bladder make prostate cancer diagnosis a challenge. rendering the PEGylated 64 Cu-liposomes promising candidates as diagnostic PET tracers across a variety of cancer types.
From a drug delivery point of view, the optimal level of PEGylation on different liposome formulations has been extensively discussed [23] . In a study by Chow et al., radiolabeled liposomes (
111
In-liposomes) were tested in animals, and effective long-term circulation in the blood and maximum tumor uptake was achieved with 6 mol% PEGylated 100 nm liposomes [22] .
The measured half-life (T 1=2β ) reported in the present study was less affected by the PEG level, while the initial clearance of the 5 mol% PEG liposomes was significantly higher than that of 10 mol% PEG liposomes. Thus a higher fraction of 10 mol% PEG liposomes is expected to be present in the circulation. In addition, we found that inclusion of 10 mol% DSPE-PEG 2000 in the liposomal membrane increased the amount of liposomes found in the tumors compared to the 5 mol% DSPE-PEG 2000 liposomes. This observation is in accordance with the generally accepted hypothesis that a longer blood circulation half-life results in repeated passage through the tumor site of high concentrations of liposomes, and thereby greater efficiency of extravasation [23, 29] . Furthermore, we observed a trend toward higher liposome uptake in smaller tumors per gram of tissue, as also reported in a previous study [24] . The high levels of liposome uptake measured in smaller tumors may be explained by their higher vascular volumes compared to larger tumors. The diagnostic safety of 64 Cu-liposomes as PET tracers was evaluated, and resulted in a total effective dose of less than 3.3·10 −2 mSv/MBq for both 5 and 10 mol% PEG liposomes, an acceptable radiation dose in clinical PET imaging according to International Commission on Radiological Protection (ICRP) guidelines [30] . The combination of PET scanners and computed tomographic (CT) scanners in clinical use provides co-registered images of anatomic and functional information as well as CT-based attenuation correction in a single study. In PET/CT scanning procedures, the effective dose is a combination of the dose from the PET and the dose from the CT. Therefore, in addition to the radiation dose from the decaying 64 Cu radionuclide, the dose from a whole-body CT scanning should be added to the total effective dose, and is normally estimated to be less than 10 mSv [31, 32] .
A total effective dose less than 20 mSv per patient (both CT and PET) therefore predicts that initial administered activity of 200 MBq of 64 Cu-liposomes should be acceptable in a clinical study.
The organs receiving the highest doses were the spleen, liver, stomach wall, lower large intestine wall, red marrow and lungs, and similar critical organs were identified from the dosimetric analysis of data from a clinical study [28] yielding comparable effective doses. While an evaluation of the absorbed radiation dose based on preclinical studies provides a reasonable guideline, especially for identifying the most critical organs, caution must be exercised in interpreting such approximated absorbed radiation doses. Since variability in calculation approaches (particularly in implementation of the remainder-of-body) can result in errors in estimated effective doses, direct comparisons between dosimetry studies should be considered carefully. Even though the 10 mol% PEG liposomes accumulated in a significant higher degree in the tumors, a less favorable T/M ratio was obtained (8.9±0.9) compared to 5 mol% PEG liposomes (11.3±1.3) 24 h after injection. From a diagnostic point of, view a high T/M ratio together with a low total effective dose is favorable, rendering the 5 mol% PEG liposomes most suitable from a diagnostic and safety perspective.
The knowledge of absorbed radiation doses to various critical organs is crucial for the development of radiotherapeutic agents in order to ensure an adequate evaluation of the safety of a potential agent and an understanding of the dose-response relationship. For 177 Lu-liposomes to act as radiotherapeutic agents, it is essential that they are highly stable in vivo and carry sufficient amounts of 177 Lu radionuclides into the tumor tissue for effective treatment. One challenge with internal radiation therapy is delivering the highest possible dose to the tumor while sparing normal organs from damage. Furthermore, for treatment to achieve efficacy, a T/M ratio of at least 3-5 should be reached [33] . We have found that 177 Lu 3+ can be loaded into PEGylated liposomes as efficiently as 64 Cu 2+ (>95 %), similar to a study reporting 111 In/ 177 Lu remote loading (>90 %) in PEGylated liposomes using Oxine [34] . While the 177 Lu-liposomes in this study showed essentially no leakage when incubated in serum, a significantly lower retention of radionuclides (83 %) was observed in a previous study [34] . This observation may be explained by the higher binding affinity of 177 Lu-DOTA in comparison to 177 Lu-DTPA [35, 36] . We foresee that selection of patients suited for 177 Lu therapy would require a pretreatment evaluation for which 64 Cu-liposome PET imaging is ideal. In addition, we have found that it is possible to load 64 Cu and 177 Lu simultaneously into the PEGylated liposomes (data not shown), thus providing a potential theranostic agent. This 64 Cu/ 177 Lu double-loading approach could give a simultaneous visualization by PET of 177 Lu-liposome therapy ( 64 Cu/ 177 Lu-liposomes). Whether this PETbased imaging approach is superior to SPECT imaging based on pure 177 Lu-liposomes has yet to be proven, but it should provide superior diagnostic sensitivity [37] , and does allow for quantification of lesion uptake by SUV.
The high absorbed doses to the tumors estimated from the dosimetric analysis (114 mGy/MBq and 11.5 mGy/ MBq for 2-g and 20-g tumors, respectively) suggest that an i.v. administration of 177 Lu-liposomes could achieve adequate delivery of therapeutic internal radiation to solids tumors. A significantly lower absorbed dose in tumors (5.74·10 −2 mGy/MBq for a 20-g tumor) was obtained in a previous study [34] , whereas comparable absorbed doses (9.7 mGy/MBq) were obtained from administration of 177 Lu-DOTA-TATE in patients with metastatic NE tumors [37] . The therapeutic potential of 177 Lu-liposomes must be further evaluated in a tumorbearing mouse model. One approach for improving the therapeutic performance of 177 Lu-liposomes might be to utilize liposomes that target specific receptors within the tumor tissue. The liposomes described here can be labeled with ligands on the surface for target-specific accumulation. A longer tumor residence duration, together with a shorter blood and liver residence period, may improve the dose-response relationship between myelotoxicity and second organ toxicity, given a safer internal radiotherapeutic treatment.
Conclusion
The aim of the study was to investigate the optimal level of PEGylation in liposomes and to determine how this influences biodistribution and tumor accumulation. A description of the organ and tumor kinetics of PEGylated liposomes was conducted to perform dosimetric calculations on diagnostic ( 64 Cu) and therapeutic ( 177 Lu) liposomes. The 10 mol% PEG liposomes showed significantly higher tumor accumulation than the 5 mol% PEG liposomes. A larger accumulation of liposomes per tumor weight was observed for small tumors compared to large tumors. The evaluation of the 64 Cu-liposomes as diagnostic tracers was successful, with clear visualization of the tumors and an acceptable estimated total effective dose to patients of less than 3.3·10 −2 mSv/MBq. Furthermore, the dosimetry results predicted that initial administered activity of 200 MBq of 64 Cu-liposomes should be acceptable in a clinical study. Thus, the overall preclinical profile of 64 Cu-liposomes strongly indicates that this new PET radiotracer is a very promising candidate for diagnostic cancer imaging in humans. Work is in progress to validate the utility of 64 Cu-liposomes in a clinical research programme. The 64 Cu-liposomes have high potential for the detection of a variety of malignancies and could be a significant addition to the currently available arsenal for cancer imaging. The remote loading of 177 Lu 3+ into PEGylated liposomes was as efficient as the 64 Cu 2+ remote loading (>95 %), and the 177 Lu-liposomes have the potential to carry a sufficient amount of 177 Lu radionuclides into the tumor tissue for effective radionuclide treatment. A high absorbed tumor dose (114 mGy/MBq) was estimated for the potential radiotherapeutic 177 Lu-liposomes. These preliminary dosimetric studies justify further therapeutic and dosimetry evaluation of 177 Lu-liposome localized radiotherapy in man. Conflicts of interest The authors declare no conflict of interest.
Ethical approval All experimental procedures performed in this study involving animals were in accordance with the ethical standards and the guidelines set forth by the Danish Ministry of Justice. This article does not contain any studies with humans performed by any of the authors.
Appendix A: Tables of absorbed radiation doses Appendix B: Equations 1-6
The percentage of injected dose in blood (%ID blood ) was calculated using:
where A b is the decay-corrected blood activity concentration at time t. The animal's blood volume was calculated as 7.5 % of its body weight, m. D is the injected activity. The percentage of injected dose in blood (%ID blood ) between 1 and 48 h was fitted to the mono-exponential equation:
where β is the first-order disposition rate constant or the elimination rate constant, and B represents the fraction of the injected dose which is cleared from the blood at the disposition rate β. The fraction of the dose cleared initially can be estimated by 100 % -B. The terminal half-life (T ½β ) of the liposomes was determined using:
The available data did not permit accurate estimation of an initial half-life (T ½α ).
Accumulation in tumor and organs Liposomal concentrations within each source organ as a function of time were determined from an ROI placed over the entire volume of the organ. The liposomal accumulation in the different organs was expressed as percentage of injected dose per gram (%ID/g) by using:
where A is the decay-corrected activity concentration in the tumor and normal organs, and ρ is the organ density and is assumed to be 1 g/cm 3 for all organs and tumors. The liposomal accumulation in the tumor was further parameterized by the standardized uptake value (SUV) and the tumor-to-muscle (T/M) ratio. The SUV values were calculated using:
where m is the animal's body weight and A is the decaycorrected activity concentration in the tumor. The PET data was not corrected for attenuation, which would give 5-15 % higher 64 Cu concentrations than the values provided in this study, depending on the tissue in question.
For the 64 Cu-liposome dosimetry study, activity concentration data, which were not corrected for 64 Cu radioactive decay (Â), were used to construct activity concentration-time curves for each source organ. For dose calculations the the program OLINDA/EXM [27] were used. The residence time (T R ) from each source organ was used as input, and was calculated as:
where Â is the activity concentration in the organ as a function of time, and V organ is the volume of the source organ. Integration was carried out using the trapezoidal method to obtain the area up to the last measured activity concentration (Â * ). An estimate of the long-term tail of the activity concentration-time curves for the different organs was made by fitting an exponential function (Â~A⋅e −βt ) to the two last biodistribution data from a clinical study and is an average of 17 patients [28] measured points. The area beyond Â * was then estimated by Â * /β. Since steady-state condition for the liposomal concentration within the measured tumor tissue was observed after 24 h (data not shown), the long-term tail of the activity concentration-time curves was assumed to be governed only by the radionuclide decay. The area beyond Â * was thus estimated by Â * ⋅ T 1=2
ln2 , where T ½ is the half-life of the radionuclide. In the OLINDA/EXM program, activity not assigned to a specific organ must be assigned to the remainder-of-body category. In our calculation, this was estimated as the full injected dose activity received by the body excluding the source organ doses. A separate T R was assigned to the remainder-of-body activity concentration-time curve.
For the 177 Lu-liposome dosimetry study, 64 Cu-liposomes were used as biological surrogates to study the biodistribution and estimate radiation dosimetry of 177 Lu-liposomes. Thus, it was assumed that the 177 Lu-liposomes follow virtually the same biodistribution and pharmacokinetics as the 64 Cu-liposomes due to the encapsulation of the radionuclides inside the liposomes prohibiting the exchange of the radionuclides with the biological environment. 64 Cu-liposome activity data for each source organ corrected for 64 Cu radioactive decay were multiplied by the physical decay of 177 Lu (e − ln2 T 1=2 ) to obtain estimates for the 177 Lu-liposome activity concentration in each source organ as a function of time. The T R from each source organ was calculated via equation S6.
